The economic burden of diabetic retinopathy in Germany in 2002

BackgroundThe aims of our study were to describe the costs associated with diabetic retinopathy (DR), and to evaluate its economic impact in Germany.MethodsForty-one German ophthalmologists, randomly selected from a physicians’ database in Germany, provided information on adult Type 1 and Type 2 diabetic patients with DR (n = 207). This information included socio-demographics, clinical characteristics and resource use during the year 2002. National-level cost estimates were calculated, based on these results and the prevalence data on DR in Germany.ResultsThis study found that costs associated with DR tend to increase as DR progresses, being highest in patients with proliferative DR and lowest in patients with mild, non-proliferative DR. The German statutory health insurance (Gesetzliche Krankenversicherung, GKV) covered two-thirds of the total costs paid by all the payers. The total cost of DR from a societal perspective was calculated at €3.51 bn for the year 2002, and from the GKV perspective amounted to €2.23 bn.ConclusionsThis study is the first comprehensive study to provide estimates of costs associated with DR in Germany. These costs were estimated to account for approximately 1.5% of the total health-care expenditure in 2002.

[1]  B. Bertram.  Prävalenz von Patienten mit Diabetes mellitus ohne und mit Retinopathie in einer Augenarztpraxis , 1997, Der Ophthalmologe.

[2]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[3]  P. Hartmann,et al.  Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg , 2001, Der Ophthalmologe.

[4]  U. Schwabe,et al.  Arzneiverordnungs-Report 2002 , 2003 .

[5]  H. Hauner,et al.  The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study , 2006, Diabetologia.

[6]  H. Hauner,et al.  Heterogenität der Kosten bei Patienten mit Diabetes mellitus: Die KoDiM-Studie , 2006 .

[7]  R. Klein,et al.  The economic burden of major adult visual disorders in the United States. , 2006, Archives of ophthalmology.

[8]  J. Caro,et al.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.

[9]  R. Klein,et al.  The impact of diabetic retinopathy: perspectives from patient focus groups. , 2004, Family practice.

[10]  B. Jönsson,et al.  Revealing the cost of Type II diabetes in Europe , 2002, Diabetologia.

[11]  Hendrik Lehnert,et al.  Prävalenz und Pharmakotherapie des Diabetes mellitus in der primärärztlichen Versorgung , 2005 .

[12]  S. Hörle,et al.  Epidemiologie diabetischer Erblindungen - eine Übersicht , 2002 .

[13]  M Höfler,et al.  [Prevalence and pharmacotherapy of diabetes mellitus in primary care]. , 2005, Deutsche medizinische Wochenschrift.

[14]  M. Redaélli,et al.  Diabetes—prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany , 2006, Diabetic medicine : a journal of the British Diabetic Association.